17
Jun

Two months removed from a deal that sent her last biotech to Bristol-Myers Squibb for up to $725 million, CEO Nancy Stagliano isn’t wasting any time, setting sights on rare diseases with True North Therapeutics, her latest venture, and locking down a $22 million A round to move forward.

…read more

Source: True North snags $22M and sets course for the clinic with a rare disease drug

    

0 No comments